Compare iShares MSCI China ETF (MCHI) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Smith & Nephew plc — how do they compare? iShares MSCI China ETF trades at $55.01, while Smith & Nephew plc trades at $29.7 (market cap $12.54B). The key difference: Smith & Nephew plc pays a 2.65% dividend while iShares MSCI China ETF pays none, and iShares MSCI China ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| MCHI | SNN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $66.99 | $38.70 |
52-Week Low | $50.48 | $28.73 |
Market Cap | — | $12.54B |
Enterprise Value | — | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI, the iShares MSCI China ETF, trades at $55.2, down 3.04% over the past day. Technical indicators show a bullish overall signal with strong moving average support, while oscillators are neutral. The ETF is positioned near key support at $55. Recent news highlights China's strong export growth, particularly in AI and tech sectors, and institutional interest, though some funds have reduced holdings. A dividend of $0.36 per share is scheduled for payment in June 2026.
The outlook for MCHI is cautiously optimistic, driven by China's robust export performance and tech sector strength, but tempered by geopolitical tensions and regulatory risks. Investment opportunities include exposure to undervalued Chinese equities and AI-driven growth, while risks involve U.S.-China trade friction and potential economic slowdowns. Investors should weigh these factors against the ETF's current technical strength.
Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.
Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
